Bayesian methods for the design and analysis of noninferiority trials.

Abstract:

:The gold standard for evaluating treatment efficacy of a medical product is a placebo-controlled trial. However, when the use of placebo is considered to be unethical or impractical, a viable alternative for evaluating treatment efficacy is through a noninferiority (NI) study where a test treatment is compared to an active control treatment. The minimal objective of such a study is to determine whether the test treatment is superior to placebo. An assumption is made that if the active control treatment remains efficacious, as was observed when it was compared against placebo, then a test treatment that has comparable efficacy with the active control, within a certain range, must also be superior to placebo. Because of this assumption, the design, implementation, and analysis of NI trials present challenges for sponsors and regulators. In designing and analyzing NI trials, substantial historical data are often required on the active control treatment and placebo. Bayesian approaches provide a natural framework for synthesizing the historical data in the form of prior distributions that can effectively be used in design and analysis of a NI clinical trial. Despite a flurry of recent research activities in the area of Bayesian approaches in medical product development, there are still substantial gaps in recognition and acceptance of Bayesian approaches in NI trial design and analysis. The Bayesian Scientific Working Group of the Drug Information Association provides a coordinated effort to target the education and implementation issues on Bayesian approaches for NI trials. In this article, we provide a review of both frequentist and Bayesian approaches in NI trials, and elaborate on the implementation for two common Bayesian methods including hierarchical prior method and meta-analytic-predictive approach. Simulations are conducted to investigate the properties of the Bayesian methods, and some real clinical trial examples are presented for illustration.

journal_name

J Biopharm Stat

authors

Gamalo-Siebers M,Gao A,Lakshminarayanan M,Liu G,Natanegara F,Railkar R,Schmidli H,Song G

doi

10.1080/10543406.2015.1074920

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

823-41

issue

5

eissn

1054-3406

issn

1520-5711

journal_volume

26

pub_type

杂志文章,评审
  • Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker.

    abstract::We consider the problem of estimating a biomarker-based subgroup and testing for treatment effect in the overall population and in the subgroup after the trial. We define the best subgroup as the subgroup that maximizes the power for comparing the experimental treatment with the control. In the case of continuous outc...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1633655

    authors: Joshi N,Fine J,Chu R,Ivanova A

    更新日期:2019-01-01 00:00:00

  • A predictive risk probability approach for microarray data with survival as an endpoint.

    abstract::Gene expression profiling has played an important role in cancer risk classification and has shown promising results. Since gene expression profiling often involves determination of a set of top rank genes for analysis, it is important to evaluate how modeling performance varies with the number of selected top ranked ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802277967

    authors: Chen DT,Schell MJ,Chen JJ,Fulp WJ,Eschrich S,Yeatman T

    更新日期:2008-01-01 00:00:00

  • Bayesian semiparametric predictive modeling with applications in dose-response prediction.

    abstract::A framework is proposed for making quality predictions in situations for which only systematically inaccurate data are available. The predictions are based on the systematically inaccurate data, complete data from similar situations, and expert knowledge. The proposed predictive model is well suited to functional data...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.860153

    authors: Haaland B,Chiang AY

    更新日期:2014-01-01 00:00:00

  • A predictive Bayesian approach to the design and analysis of bridging studies.

    abstract::Pharmaceutical product development culminates in confirmatory trials whose evidence for the product's efficacy and safety supports regulatory approval for marketing. Regulatory agencies in countries whose patients were not included in the confirmatory trials often require confirmation of efficacy and safety in their p...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2012.701579

    authors: Gould AL,Jin T,Zhang LX,Wang WW

    更新日期:2012-09-01 00:00:00

  • A global model to define the behavior of partial agonists (bell-shaped dose-response inducers) in pharmacological evaluation of activity in the presence of the full agonist.

    abstract::The dose-response models for full agonists and for a particular type of partial agonist can be described by sigmoidal curves and bell-shaped curves, respectively. The methods currently used to evaluate the interaction of a full agonist and a partial agonist require a large number of experimental units and base their a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409808835266

    authors: Ghosh K,Shen ES,Arey BJ,López FJ

    更新日期:1998-11-01 00:00:00

  • On sample size calculation based on odds ratio in clinical trials.

    abstract::Sample size calculation formulas for testing equality, noninferiority, superiority, and equivalence based on odds ratio were derived under both parallel and one-arm crossover designs. An example concerning the study of odds ratio between a test compound (treatment) and a standard therapy (control) for prevention of re...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120016231

    authors: Wang H,Chow SC,Li G

    更新日期:2002-11-01 00:00:00

  • Analysis of recurrent hypoglycemic events.

    abstract::Hypoglycemia is a major safety concern for diabetic patients. Hypoglycemic events can be modeled based on time to recurrent events or count data. In this article, we evaluated a gamma frailty model with variance estimated by the inverse of observed Fisher information matrix, a gamma frailty model with the sandwich var...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1765370

    authors: Ma C,Qu Y,Fu H

    更新日期:2020-05-18 00:00:00

  • Statistical considerations in setting product specifications.

    abstract::According to ICH Q6A (1999), a specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. For drug products, specifications usually consist of test methods and acceptance criteria ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2014.972511

    authors: Dong X,Tsong Y,Shen M

    更新日期:2015-01-01 00:00:00

  • A bootstrap-based test for establishing noninferiority in clinical trials.

    abstract::A randomized, active-control clinical trial setting with the objective of testing noninferiority for a continuous response variable is considered. Noninferiority margin is based on the concept of preserving a certain fraction of the active control effect. Noninferiority is established if the ratio of the lower (upper)...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400600609478

    authors: Chen M,Kianifard F,Dhar SK

    更新日期:2006-05-01 00:00:00

  • A quantitative assessment of factors influencing the probability of postmarketing out-of-specification observations.

    abstract::When marketed lots of pharmaceutical products produce a number of out-of-specification (OOS) samples, it can be very disruptive. In some cases such lots must be recalled, at substantial expense. We present a model of the probability of OOS samples and show quantitatively how this probability depends on the underlying ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120022763

    authors: Fairweather WR

    更新日期:2003-08-01 00:00:00

  • Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studies.

    abstract::We study the statistical efficiency for rising-dose designs in the context of first-in-human studies. Specifically, we identify a class of crossover designs that are appealing in terms of both subject safety and statistical efficiency and, for a three-period, two-panel design in such a class, we compare its A-efficien...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.792827

    authors: Yan Z,Hosmane B,Locke C

    更新日期:2013-01-01 00:00:00

  • Robust small-sample inference for fixed effects in general Gaussian linear models.

    abstract::Although asymptotically, the empirical covariance estimator is consistent and robust with respect to the selection of the working correlation matrix, when the sample size is small, its bias may not be negligible. This article proposes a small sample correction for the empirical covariance estimator in general Gaussian...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.557792

    authors: Fan C,Zhang D,Zhang CH

    更新日期:2012-01-01 00:00:00

  • Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints.

    abstract::Sample size calculation based on normal approximations is often associated with the loss of statistical power for a single-arm trial with a time-to-event endpoint. Recently, Wu (2015) derived the exact variance for the one-sample log-rank test under the alternative and showed that a single-arm one-stage study based on...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1730869

    authors: Shan G

    更新日期:2020-09-02 00:00:00

  • Assessment of antitumor activity for tumor xenograft studies using exponential growth models.

    abstract::In preclinical tumor xenograft experiments, the antitumor activity of the tested agents is often assessed by endpoints such as tumor doubling time, tumor growth delay (TGD), and log10 cell kill (LCK). In tumor xenograft literature, the values of these endpoints are presented without any statistical inference, which ig...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.481802

    authors: Wu J

    更新日期:2011-05-01 00:00:00

  • Use of predictive probabilities in phase II and phase III clinical trials.

    abstract::Predictive probability is particularly useful in aiding a decision-making process related to drug development. This is especially true for decisions occurring as the result of interim analyses of clinical trials. Examples of clinical trial applications of Bayesian predictive probability and the use of the beta-binomia...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100101000

    authors: Johns D,Andersen JS

    更新日期:1999-03-01 00:00:00

  • Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial.

    abstract::ETRANK is a statistical software which uses nonparametric (randomization) technique to analyze incomplete repeated measures data, where the pattern of withdrawal is treatment related. This stand alone program is written in C, presently runs in MS-DOS, and a Windows version is in development. The program has been devel...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543409608835156

    authors: Entsuah R

    更新日期:1996-11-01 00:00:00

  • Using graphical displays of exact overall significance levels as a guideline for choosing a significance level for pairwise comparisons of a dichotomous variable.

    abstract::Exact overall significance levels for selected sample sizes and response probabilities are graphically displayed when a dichotomous variable is compared between a placebo and two or more active treatments. A Z-statistic with a pooled variance estimator is used as the test statistic and critical values are based on the...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120024207

    authors: Whaley FS

    更新日期:2003-11-01 00:00:00

  • Bayesian penalized log-likelihood ratio approach for dose response clinical trial studies.

    abstract::In literature, there are a few unified approaches to test proof of concept and estimate a target dose, including the multiple comparison procedure using modeling approach, and the permutation approach proposed by Klingenberg. We discuss and compare the operating characteristics of these unified approaches and further ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1293081

    authors: Tang Y,Cai C,Sun L,He J

    更新日期:2017-01-01 00:00:00

  • Sample size determination for Bayesian analysis of small n sequential, multiple assignment, randomized trials (snSMARTs) with three agents.

    abstract::The small n, Sequential, Multiple Assignment, Randomized Trial (snSMART) is a two-stage clinical trial design for rare diseases motivated by the comparison of three active treatments for isolated skin vasculitis in the ongoing clinical trial ARAMIS (a randomized multicenter study for isolated skin vasculitis, NCT09239...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1815032

    authors: Wei B,Braun TM,Tamura RN,Kidwell K

    更新日期:2020-09-06 00:00:00

  • Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.

    abstract::To confirm results obtained from local evaluation at investigational centers, many oncology studies utilize blinded independent central review (BICR) to make assessments of the primary endpoint, progression-free survival (PFS). The comparison of data often leads to large discordances between these observations, castin...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.813516

    authors: Mannino FV,Amit O,Lahiri S

    更新日期:2013-01-01 00:00:00

  • Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.

    abstract::A common question in clinical studies is how to use historical data from earlier studies, leveraging relevant information into the design and analysis of a new study. Bayesian approaches are particularly well-suited to this task, with their natural ability to borrow strength across data sources. In this paper, we prop...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1226324

    authors: Li JX,Chen WC,Scott JA

    更新日期:2016-01-01 00:00:00

  • Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.

    abstract::This article deals with seven special issues related to the assumptions, applicability, and practical use of formulas for calculating power or sample size, respectively, for comparative clinical trials with time-to-event endpoints, with particular focus on the well-known Freedman and Schoenfeld methods. All problems a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.1000546

    authors: Abel UR,Jensen K,Karapanagiotou-Schenkel I,Kieser M

    更新日期:2015-01-01 00:00:00

  • A comparison of test procedures for multidose animal carcinogenicity assays under competing risks.

    abstract::Four multidose animal carcinogenicity assay trend test procedures based on the chi-square, Hoel-Walburg, log-rank, and Peto procedures are compared under conditions of competing risks. A total of 42 different risk populations are simulated in which a simulated animal can contract one or more of five different tumor ty...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409408835089

    authors: Graves TS

    更新日期:1994-11-01 00:00:00

  • Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.

    abstract::Frequentist design for two-arm randomized Phase II clinical trials with outcomes from the exponential dispersion family was proposed previously, where the total sample sizes are minimized under multiple constraints on the standard errors of the estimated group means and their difference. This design was generalized fr...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1402779

    authors: Jiang W,Wick JA,He J,Mahnken JD,Mayo MS

    更新日期:2018-01-01 00:00:00

  • Statistical methods to analyze adverse events data of randomized clinical trials.

    abstract::The adverse events data of randomized clinical trials are often analyzed based on either crude incidence rates or exposure-adjusted incidence rates. These rates do not adequately account for an individual patient's profile of adverse events over the study period when an individual may remain in the trial after experie...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903105463

    authors: Siddiqui O

    更新日期:2009-09-01 00:00:00

  • Inference for clinical trials with some protocol amendments.

    abstract::The use of adaptive methods in clinical development has become very popular in recent years due to its flexibility in modifying trial procedures and/or statistical procedures of on-going clinical trials. Modifications to trial procedures are usually documented by protocol amendments. However, the actual patient popula...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200062286

    authors: Chow SC,Shao J

    更新日期:2005-01-01 00:00:00

  • Determining a minimum clinically important difference between treatments for a patient-reported outcome.

    abstract::Patient-reported outcomes are important for assessing the effectiveness of treatments in many disease areas. For this reason, many new instruments that capture patient-reported outcomes have been developed over the past several decades. With the development of each new instrument, there is the ensuing question of what...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903315757

    authors: Kirby S,Chuang-Stein C,Morris M

    更新日期:2010-09-01 00:00:00

  • Sample size considerations for historical control studies with survival outcomes.

    abstract::Historical control trials (HCTs) are frequently conducted to compare an experimental treatment with a control treatment from a previous study, when they are applicable and favored over a randomized clinical trial (RCT) due to feasibility, ethics and cost concerns. Makuch and Simon developed a sample size formula for h...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2015.1052495

    authors: Zhu H,Zhang S,Ahn C

    更新日期:2016-01-01 00:00:00

  • Ratio of means vs. difference of means as measures of superiority, noninferiority, and average bioequivalence.

    abstract::Ratio of means (ROM) and difference of means (DOM) are often used in a superiority, noninferiority (NI), or average bioequivalence (ABE) test to evaluate whether the test mean is superior, NI, or equivalent to the reference (placebo or active control) mean. The literature provides recommendations regarding how to choo...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1265536

    authors: Sun W,Grosser S,Tsong Y

    更新日期:2017-01-01 00:00:00

  • FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.

    abstract::The Food and Drug Administration of the United States issued a draft guidance on adaptive design clinical trials in February 2010. This draft guidance has attracted a lot of attention because of the increasing interest in adaptive trials by the pharmaceutical industry in recent years. In this paper, we report on highl...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.514456

    authors: Chuang-Stein C,Beltangady M

    更新日期:2010-11-01 00:00:00